二甲双胍联合利拉鲁肽或地特胰岛素治疗2型糖尿病合并少肌症的疗效对比研究

Comparison of Metformin Combined with Insulin Detemir or Liraglutide to Treat Type 2 Diabetes Mellitus with Sarcopenia

目的:对比分析二甲双胍联合利拉鲁肽或地特胰岛素治疗2型糖尿病(T2DM)合并少肌症的临床疗效。方法:选取广东省佛山市第一人民医院收治的300例2型糖尿病合并少肌症患者,将其随机分为实验组(n=150)与对照组(n=150)。实验组患者接受二甲双胍联合利拉鲁肽,对照组患者例接受二甲双胍联合地特胰岛素,比较两组患者临床疗效。结果:经治疗后,两组患者空腹血糖(FPG)、餐后两小时血糖(2h P G)、糖化血红蛋白(H b A1c)、体重、腰围、胰岛素日用量均明显下降,空腹C肽、餐后两小时C肽(2h C肽)水平上升,且实验组F P G、2h PG、Hb A1c、体重、腰围低于对照组(P<0.05),空腹C肽、2h C肽明显高于对照组(P<0.05);治疗后两组患者骨骼肌质量指数较治疗前均有所提升(P<0.05),且实验组高于对照组(P<0.05);实验组不良反应发生率明显低于对照组(P<0.05)。结论:二甲双胍联合利拉鲁肽治疗2型糖尿病合并少肌症疗效更佳,安全性高,值得推广。

Objective:To compare the clinical efficacy of metformin combined with insulin detemir or liraglutide to treat type 2 diabetes mellitus(T2DM)with sarcopenia.Methods:300 patients with T2DM combined and sarcopenia were selected and randomly divided into experimental group(n=150)and control group(n=150).The patients in the experimental group received metformin combined with liraglutide.The control group received metformin combined with insulin detemir.The clinical efficacy of the two groups was compared.Results:After treatment,the FPG,2 h PG,HbA1c,weight,waist circumference and daily insulin decreased significantly in the two groups.The level of fasting C-peptide and postprandial 2 h C-peptide increased in the two groups,and the FPG,2 h PG,HbA1c body weight and waist circumference of the experimental group were lower than the control group(P<0.05).The fasting C peptide and postprandial 2 h C-peptide of the experimental group were significantly higher than those of the control group(P<0.05).The skeletal muscles were measured after treatment.The skeletal muscles index of both groups were higher than that before the treatment(P<0.05),and the experimental group was higher than that of the control group(P<0.05),and the incidence of adverse reaction in the experimental group was significantly lower than that of the control group(P<0.05).Conclusion:Metformin combined with liraglutide is effective and safe in the treatment of patients with T2DM and sarcopenia.